Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

If you purchased or acquired securities in BioAge between September 26, 2024 and January 7, 2025 and would like to discuss ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.

The hormone insulin plays a central role in the metabolism of many living organisms. When food is plentiful, insulin promotes ...